- Home
- GIGM vs RVPH Comparison
GIGM vs RVPH Comparison
Compare GIGM & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GIGM
- RVPH
- Stock Information
- Founded
- GIGM 1998
- RVPH 2006
- Country
- GIGM Taiwan
- RVPH United States
- Employees
- GIGM N/A
- RVPH N/A
- Industry
- GIGM Computer Software: Programming Data Processing
- RVPH Biotechnology: Pharmaceutical Preparations
- Sector
- GIGM Technology
- RVPH Health Care
- Exchange
- GIGM Nasdaq
- RVPH Nasdaq
- Market Cap
- GIGM 20.2M
- RVPH 18.1M
- IPO Year
- GIGM 2000
- RVPH N/A
- Fundamental
- Price
- GIGM $1.66
- RVPH $0.44
- Analyst Decision
- GIGM
- RVPH Strong Buy
- Analyst Count
- GIGM 0
- RVPH 6
- Target Price
- GIGM N/A
- RVPH $4.50
- AVG Volume (30 Days)
- GIGM 10.6K
- RVPH 18.7M
- Earning Date
- GIGM 10-28-2025
- RVPH 11-13-2025
- Dividend Yield
- GIGM N/A
- RVPH N/A
- EPS Growth
- GIGM N/A
- RVPH N/A
- EPS
- GIGM N/A
- RVPH N/A
- Revenue
- GIGM $3,250,000.00
- RVPH N/A
- Revenue This Year
- GIGM N/A
- RVPH N/A
- Revenue Next Year
- GIGM N/A
- RVPH N/A
- P/E Ratio
- GIGM N/A
- RVPH N/A
- Revenue Growth
- GIGM N/A
- RVPH N/A
- 52 Week Low
- GIGM $1.35
- RVPH $0.25
- 52 Week High
- GIGM $1.89
- RVPH $4.28
- Technical
- Relative Strength Index (RSI)
- GIGM 51.62
- RVPH 43.60
- Support Level
- GIGM $1.58
- RVPH $0.57
- Resistance Level
- GIGM $1.68
- RVPH $0.69
- Average True Range (ATR)
- GIGM 0.06
- RVPH 0.10
- MACD
- GIGM -0.01
- RVPH -0.02
- Stochastic Oscillator
- GIGM 62.50
- RVPH 3.11
About GIGM GigaMedia Limited
GigaMedia Ltd is a diversified provider of digital entertainment services. Its only segment and principal business is digital entertainment service business, which operates a portfolio of digital entertainment products, targeting digital entertainment service users across Asia. It operates digital entertainment business in Taiwan, Hong Kong and Macau through FunTown.
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.